摘要
过去十几年,我国虽然经过多轮药品、耗材集中招标采购,但药价却不降反升。本文通过对药耗价格虚高成因、省级医药招标采购制度存在问题等方面进行分析,探寻在国家医疗保障局组织下,医药招采制度的改革方向和路径。
Over the past decade,although China has gone through many rounds of centralized bidding for drugs and consumables,drug prices have not decreased but increased.Through the analysis of the causes of the high drug consumption price and the problems of the provincial medical&pharmaceutical bidding and procurement system,this paper explores the direction and path of the reform of the medical&pharmaceutical bidding and purchasing system under the organization of the National Healthcare Security Bureau.
作者
任翔
Ren Xiang(Jiangxi Medical&Pharmaceutical Purchasing Service Center,Nanchang,330096)
出处
《中国医疗保险》
2020年第1期65-67,共3页
China Health Insurance
关键词
医药招采制度
价格虚高
服务平台
改革路径
medical&pharmaceutical bidding and purchasing system
virtual-high price
service platform
reform path
